+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P07946(KLF17 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07946(KLF17 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The Krüppel-like factor 17 (KLF17) is a member of the Krüppel-like transcription factor family, characterized by conserved C-terminal zinc finger domains that mediate DNA binding. KLF17 acts as a transcriptional repressor, playing critical roles in regulating gene networks involved in cellular differentiation, proliferation, and metastasis. It is particularly noted for its tumor-suppressive functions, where it inhibits epithelial-mesenchymal transition (EMT) by repressing EMT-promoting genes like ID1 and TWIST1. while enhancing epithelial markers such as E-cadherin. KLF17 is also implicated in metabolic regulation and stress responses, interacting with pathways like TGF-β and HIF-1α.

KLF17 antibodies are immunological tools developed to detect and quantify KLF17 protein expression in research and diagnostic contexts. These antibodies are essential for techniques including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). Their applications span cancer biology—studying metastasis and therapeutic resistance—as well as developmental biology and metabolic disorders. Validated antibodies specifically target epitopes within KLF17's N-terminal repression domain or C-terminal DNA-binding region, enabling precise analysis of its expression patterns and functional interactions.

Dysregulation of KLF17 is associated with malignancies (e.g., breast, lung, and colorectal cancers), making its antibodies valuable for biomarker studies and prognostic assessments. Ongoing research explores KLF17's role in non-cancer contexts, such as neuronal development and metabolic syndrome, broadening the utility of these reagents in translational medicine.